Sun Pharma Advanced Research enters into agreement with Visiox Pharma

08 Dec 2021 Evaluate

Sun Pharma Advanced Research Company (SPARC) has entered into an agreement with Visiox Pharma (Visiox) to grant exclusive worldwide rights (except for India and Greater China) for the development and commercialization of PDP-716 and SDN-037. Under the terms of the license agreement, SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox.

The collaboration with Visiox allows company to make PDP-716 and SDN-037 available to patients seeking to overcome the challenges associated with the currently marketed formulations of these drugs.

SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.


Sun Pharma Adv. Res Share Price

204.40 14.00 (7.35%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 869.40
Sagility India 28.03
AGS Transact Tech 79.99
Just Dial 1073.50
Krystal Integrated 643.20
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.